Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/TCTR20210316012
TCTR20210316012CompletedPhase 4

Effects of low dose oral tolvaptan add on benefit in patients hospitalized for acute decompensated heart failure: A randomized controlled trial

/A0 sites40 target enrollmentStarted: March 16, 2021Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
Enrollment
40
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 Years to N/A (No limit) (—)
Sex
All

Inclusion Criteria

  • •1 Age more than 18 years
  • •2 Acute decompensated HF
  • •3 Admission within 48 hr
  • •4 Plasma Na less than 145 mEq/L
  • •5 Informed consent

Exclusion Criteria

  • •1 Hemodynamic unstable
  • •2 AKI or advanced ESRD
  • •3 Severe hepatitis
  • •4 Pregnancy or breastfeeding
  • •5 Major surgery within 60 days
  • •6 Hypersensitivity to the active substance

Investigators

Sponsor
/A

Similar Trials

Completed
Not Applicable
Study of the safety and efficacy of tolvaptan for fluid retention symptoms of right heart failure due to pulmonary hypertensiopulmonary hypertension
JPRN-UMIN000010196Department of Cardiology, Keio University School of Medicine40
Completed
Not Applicable
ong-term Effect of Tolvaptan Administration for Outcome and Neurohormonal Factors in Patients with Heart Failureheart failure
JPRN-UMIN000013807ihon University Surugadai Hospital100
Not yet recruiting
Phase 4
A study on the safety and efficasy of tolvaptan for patients with fluid retention after cardiothoracic surgeryPatients received cardiothoracic surgery with congestive heart failure.
JPRN-UMIN000011172Osaka city university graduate school of medicine210
Completed
Not Applicable
ongitudinal Efficacy and Safety Study of Tolvaptan on Autosomal Dominant Polycystic Kidney Disease PatientsAutosomal Dominant Polycystic Kidney Disease
JPRN-UMIN000021267Autosomal Dominant Polycystic Kidney Disease Research Section, Kyorin University, School of Medicine119
Recruiting
Not Applicable
A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene.ephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene
JPRN-UMIN000021708Department of Nephrology and Endocrinology, The University of Tokyo Hospital3